Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509.
Article
CAS
PubMed Central
PubMed
Google Scholar
Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70:404–13.
Article
PubMed
Google Scholar
Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964–75.
Article
CAS
PubMed Central
PubMed
Google Scholar
Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005;52:2625–36.
Article
PubMed
Google Scholar
van der Heijde D, Klareskog L, Boers M, Landewe R, Codreanu C, Bolosiu HD, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis. 2005;64:1582–7.
Article
PubMed Central
PubMed
Google Scholar
Makinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis. 2005;64:1410–3.
Article
CAS
PubMed Central
PubMed
Google Scholar
Landewe R, van der Heijde D, van der Linden S, Boers M. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis. 2006;65:637–41.
Article
CAS
PubMed Central
PubMed
Google Scholar
Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013;72:64–71.
Article
CAS
PubMed Central
PubMed
Google Scholar
Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum. 2011;63:3702–11.
Article
PubMed
Google Scholar
Linsley PS, Nadler SG. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev. 2009;229:307–21.
Article
CAS
PubMed
Google Scholar
Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford). 2011;50:437–49.
Article
CAS
Google Scholar
Schiff M. Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2013;52:986–7.
Article
CAS
Google Scholar
de Punder YM, Fransen J, Kievit W, Houtman PM, Visser H, van de Laar MA, et al. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford). 2012;51:1610–7.
Article
Google Scholar
Kuriya B, Sun Y, Boire G, Haraoui B, Hitchon C, Pope JE, et al. Remission in early rheumatoid arthritis – a comparison of new ACR/EULAR remission criteria to established criteria. J Rheumatol. 2012;39:1155–8.
Article
PubMed
Google Scholar
Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68:1870–7.
Article
CAS
PubMed Central
PubMed
Google Scholar
Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36:729–40.
Article
CAS
PubMed
Google Scholar
Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68:954–60.
Article
CAS
PubMed Central
PubMed
Google Scholar
Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7:R796–806.
Article
CAS
PubMed Central
PubMed
Google Scholar
Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology. 2003;42:244–57.
Article
CAS
PubMed
Google Scholar
Genant HK, Jiang Y, Peterfy C, Lu Y, Redei J, Countryman PJ. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum. 1998;41:1583–90.
Article
CAS
PubMed
Google Scholar
Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum. 2011;63:43–52.
Article
CAS
PubMed
Google Scholar
van Tuyl LH, Felson DT, Wells G, Smolen J, Zhang B, Boers M. Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken). 2010;62:108–17.
Article
Google Scholar
van Tuyl LH, Britsemmer K, Wells GA, Smolen JS, Zhang B, Funovits J, et al. Remission in early rheumatoid arthritis defined by 28 joint counts: limited consequences of residual disease activity in the forefeet on outcome. Ann Rheum Dis. 2012;71:33–7.
Article
PubMed
Google Scholar
Zhang B, Combe B, Rincheval N, Felson DT. Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort. Arthritis Res Ther. 2012;14:R156.
Article
PubMed Central
PubMed
Google Scholar
Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS. Assessing remission in clinical practice. Rheumatology (Oxford). 2007;46:975–9.
Article
CAS
Google Scholar
Smolen J, Dougados M, Gaillez C, Poncet C, Le Bars M, Elegbe A, et al. Remission using different composite disease indices in MTX-IR RA patients treated with abatacept or infliximab, +MTX. Ann Rheum Dis. 2012;71:669.
Article
Google Scholar
Smolen J, Dougados M, Gaillez C, Poncet C, Le Bars M, Mody M, et al. Remission according to different composite disease activity indices in biologic-naïve patients with rheumatoid arthritis treated with abatacept or infliximab plus methotrexate. Arthritis Rheum. 2011;63:S477.
Article
Google Scholar
Smolen JS, Westhovens R, Le Bars M, Gaillez C, Poncet C, Covucci A, et al. SDAI remission is achieved in an increasing proportion of patients with early RA treated with abatacept + MTX vs MTX alone over 12 months, with reduced X-ray progression observed regardless of initial SDAI-assessed disease activity. Ann Rheum Dis. 2011;70:721.
Google Scholar
Smolen JS, Yazici Y, Durez P, Gaillez C, Le Bars M, Poncet C, et al. Evaluation of radiographic progression over 1 year in MTX-naive patients with early RA treated with abatacept + MTX versus MTX alone, according to clinical outcomes at month 3. Ann Rheum Dis. 2011;70:467.
Google Scholar
Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008;67:1360–4.
Article
CAS
PubMed
Google Scholar
Aletaha D, Alasti F, Smolen JS. Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients. Ann Rheum Dis. 2013;72:7–12.
Article
CAS
PubMed
Google Scholar
Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum. 2006;54:3119–25.
Article
CAS
PubMed
Google Scholar
Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis. 2012;71:687–93.
Article
CAS
PubMed Central
PubMed
Google Scholar
Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005;52:1020–30.
Article
CAS
PubMed
Google Scholar
Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis. 2009;68:823–7.
Article
CAS
PubMed
Google Scholar
Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263–9.
Article
PubMed
Google Scholar
Burmester G, Furst DE, Combe BG, Huizinga TWJ, Bykerk VP, Wong D, et al. Stringent criteria for low disease activity and remission after 12 months of treatment, and after treatment withdrawal, with abatacept monotherapy, abatacept with methotrexate or methotrexate alone in early rheumatoid arthritis. Arthritis Rheum. 2014;66:S1076.
Google Scholar